compounding semaglutide fda news Compounded Semaglutide: Legal & Safe 2025 Compounded "semaglutide" is not FDA-approved

Body mass index, obesity and risk of prostate cancer: A systematic review and meta-analysis

95% CI 0.57, 0.85), and heart failure hospitalizations (HR 0.65

The responsible clinical approach is to titrate slowly, evaluate response at each stage with monitoring, and stop increasing when results are adequate rather than when the theoretical maximum has been reached

Transitioning Medicare coverage of GLP-1s for obesity from the mandatory Medicare GLP-1 Bridge to the voluntary BALANCE model sets up the possibility that beneficiaries with coverage under the short-term program may need to switch Part D plans during the 2027 open enrollment period, with potential cost and coverage implications for other medications they use.

In Cox proportional hazards analysis, GLP-1RA treatment was associated with a lower hazard (HR 0.77, 95% CI 0.610.96